DelphineLChenMD

Nuclear Medicine • Seattle, WA

Professor, Radiology, University of Washington, Director of Molecular Imaging, Seattle Cancer Care Alliance

Join to view full profile

Dr. Chen is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Chen's full profile

Already have an account?

Office
1144 EASTLAKE AVE E # LG2-200
Seattle, WA 98109
Phone+1 206-606-6777

Education & Training

Washington University/B-JH/SLCH ConsortiumResidency, Nuclear Medicine, 2004 - 2006
Washington University/B-JH/SLCH ConsortiumInternship, Surgery, 1999 - 2000
Washington University in St. Louis School of MedicineClass of 1999

Certifications & Licensure

WA State Medical License 2019 - 2026
MO State Medical License 2001 - 2020
American Board of Nuclear Medicine Nuclear Medicine

Clinical Trials

Quantifying Airway Inflammation With Radiologic Tests Start of enrollment: 2007 Mar 01
Completed
Early Phase 1
Evaluation of Rosiglitazone Anti-inflammatory Effect With FDG-PET Imaging Start of enrollment: 2011 Jul 01
Completed
Early Phase 1
PET Imaging of Endotoxin-induced iNOS Activation Start of enrollment: 2010 Dec 01
Completed
Phase 1
Evaluation of FLT PET and MRI as Imaging Biomarkers of Early Treatment Response in Patients With Glioblastoma Start of enrollment: 2008 Apr 01
Completed
Assessing NOS Uptake With PET Imaging in Lung Inflammation Start of enrollment: 2014 May 01
Completed
Early Phase 1
PET Assessment of Acute Lung Transplant Rejection Start of enrollment: 2014 Feb 01
Terminated
PET Imaging CCR2 in Lung Inflammation Start of enrollment: 2018 Feb 27
Recruiting
Early Phase 1
Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies Start of enrollment: 2021 Dec 09
Recruiting
Phase 2
Roles: Principal Investigator, Contact
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours Start of enrollment: 2024 Jun 28
Not yet recruiting
Phase 1
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

PET-Based TheraP Eligibility and Outcomes of VISION-Eligible Patients with Metastatic Castration-Resistant Prostate Cancer Who ReceivedLu-PSMA-617: Importance ofF-FDG-...
Ridvan Arda Demirci, Alireza Ghodsi, Roman Gulati, Sanaz Behnia, Peter S Nelson
Journal of Nuclear Medicine. 2025-01-03
1 citations
SPECT/CT in Early Response Assessment of Patients with Metastatic Castration-Resistant Prostate Cancer ReceivingLu-PSMA-617.
Ridvan Arda Demirci, Roman Gulati, Jessica E Hawley, Todd Yezefski, Michael C Haffner
Journal of Nuclear Medicine. 2024-12-03
A deep learning anthropomorphic model observer for a detection task in PET.
Muhan Shao, Darrin W Byrd, Jhimli Mitra, Fatemeh Behnia, Jean H Lee
Medical Physics. 2024-10-01

Press Mentions

Radioligand Therapy, a ‘Game-Changer’ for Cancer Treatment, Forces Manufacturers to Race Against a Ticking ClockFebruary 11th, 2023
Fred Hutch/UW Cancer Consortium Breast Cancer Researchers Receive GrantsNovember 17th, 2022
Why the Telix (ASX:TLX) Share Price Is Dropping Lower TodayJanuary 25th, 2021
Join now to see all

Grant Support

Apoptosis And Inflammation ImagingNational Institute Of Biomedical Imaging And Bioengineering2006–2010

Professional Memberships